The Department of Health and Human Services (HHS) Food and Drug Administration (FDA) awarded a multiple-award indefinite-delivery indefinite-quantity (IDIQ) contract for the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics. The prime contractor, The Lewin Group, Inc. (doing business as Lewing Group Inc.), a subsidiary of UnitedHealth Group Incorporated, will provide data sources containing administrative claims data or claims and electronic health record (EHR) data covering tens of millions of U.S. patients. The data must be longitudinal and allow for review of full medical charts to support the FDA's post-market surveillance of biologics. The $50 million IDIQ has a 5-year ordering period and does not include any set-asides. Subsequent delivery orders have been issued to The Lewin Group to perform work under this BEST Initiative #3 program, valued at $15.3 million, $25.7 million, and $5.1 million, with performance locations in Mosby, Virginia. This contract vehicle enables the FDA to efficiently access specialized data and analytics capabilities from the Lewin Group to enhance its biologics safety monitoring efforts.
Generated 3/28/24, 9:07 AM